| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/31/2001 | WO2001037880A1 Tablets comprising micro-organisms and method for preparation of the tablets |
| 05/31/2001 | WO2001037879A1 Polyion complex micelles of core/shell structure |
| 05/31/2001 | WO2001037864A1 A novel method of diagnosing, monitoring, staging, imaging and treating cancer |
| 05/31/2001 | WO2001037851A2 Use of ubiquinone q10 for the local treatment and prevention of post-surgical ophthalmologic pathologies |
| 05/31/2001 | WO2001037841A1 Pharmaceutical compositions comprising trimegestone |
| 05/31/2001 | WO2001037834A1 Stable acid labile benzimidazole pharmaceutical compositions |
| 05/31/2001 | WO2001037828A1 Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases |
| 05/31/2001 | WO2001037821A1 Cell permeable peptides for inhibition of inflammatory reactions and methods of use |
| 05/31/2001 | WO2001037820A2 Ionizable indolinone derivatives and their use as ptk ligands |
| 05/31/2001 | WO2001037816A2 Coating of tablet cores |
| 05/31/2001 | WO2001037815A1 Osmotic dosage form comprising first and second |
| 05/31/2001 | WO2001037812A2 Gastroretentive controlled release pharmaceutical dosage forms |
| 05/31/2001 | WO2001037809A1 Colloidal suspension of submicronic particles as vectors for active principles and method for preparing same |
| 05/31/2001 | WO2001037808A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 05/31/2001 | WO2001037806A1 Composition and method for treatment of otitis media |
| 05/31/2001 | WO2001037805A1 Pharmaceutical formulations of salmeterol |
| 05/31/2001 | WO2001037803A2 Responsive polymeric hollow particles |
| 05/31/2001 | WO2001037802A1 Sustained percutaneous delivery of a biologically active substance |
| 05/31/2001 | WO2001037782A2 Method and composition for the treatment of scars |
| 05/31/2001 | WO2001037781A2 A stable aqueous dispersion of nutrients |
| 05/31/2001 | WO2001037770A1 Improved transdermal contraceptive delivery system and process |
| 05/31/2001 | WO2001037721A2 Magnetic nanoparticles for selective therapy |
| 05/31/2001 | WO2001037681A1 Phytosterol and phytostanol compositions |
| 05/31/2001 | WO2001037660A1 Sustained-release preparation of aqueous dispersion type and process for producing the same |
| 05/31/2001 | WO2001005411A8 Compositions addressing inflammation and/or degenerative disorders |
| 05/31/2001 | WO2000077032A3 Spermine:peptide-based surfactant compounds |
| 05/31/2001 | WO2000072806A3 Sunscreen composition containing sol-gel microcapsules |
| 05/31/2001 | WO2000069472A3 Enzyme-activated anti-tumor prodrug compounds |
| 05/31/2001 | WO2000069414A3 Granules containing a plant substance and method for producing the same |
| 05/31/2001 | WO2000064414A3 Solid pharmaceutical formulations of acid-sensitive proton-pump blockers |
| 05/31/2001 | WO2000042071A3 Compounds and methods to inhibit or augment an inflammatory response |
| 05/31/2001 | WO2000032772A3 Erythropoietic compounds |
| 05/31/2001 | WO1999064041A9 Multibinding agents that modulate nmda receptors |
| 05/31/2001 | WO1999062923A3 Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| 05/31/2001 | WO1998027972A8 Anti-amyloidogenic agents |
| 05/31/2001 | US20010002419 Homogeneous preparation of protein, e.g. leptin, modified at the N-terminal only by an anhydride, e.g. succinic anhydride, ethylenediaminetetraacetic dianhydride; improved solubility; no inflammation at injection sites |
| 05/31/2001 | US20010002290 Comprising allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water; skin protectant |
| 05/31/2001 | DE19954421A1 Filmförmige Zubereitung zur biphasigen Freisetzung pharmakologisch wirksamer oder anderer Substanzen Preparation in film form for biphasic release of pharmacologically active substances or other |
| 05/31/2001 | CA2706113A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 05/31/2001 | CA2396431A1 Sustained percutaneous delivery of a biologically active substance |
| 05/31/2001 | CA2394914A1 A novel method of diagnosing, monitoring, staging, imaging and treating cancer |
| 05/31/2001 | CA2392697A1 Phosphorus-containing dendrimers as transfection agents |
| 05/31/2001 | CA2392490A1 Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells |
| 05/31/2001 | CA2392400A1 A human normal counterpart of cd4+ cd56+ cutaneous neoplasm |
| 05/31/2001 | CA2392353A1 Stable acid labile benzimidazole pharmaceutical compositions |
| 05/31/2001 | CA2391986A1 Colloidal suspension of submicronic particles as vectors for active principles and method for preparing same |
| 05/31/2001 | CA2391964A1 Polyion complex micelles of core-shell structure |
| 05/31/2001 | CA2391943A1 Cell permeable peptides for inhibition of inflammatory reactions and methods of use |
| 05/31/2001 | CA2391922A1 Excipient system that contains coating substances with enzymatically removable side-groups |
| 05/31/2001 | CA2391457A1 Phytosterol and phytostanol compositions |
| 05/31/2001 | CA2389568A1 Osmotic dosage form comprising first and second coats |
| 05/31/2001 | CA2387575A1 Coating |
| 05/30/2001 | EP1103262A1 Antifungal solutions |
| 05/30/2001 | EP1103253A2 Aqueous film coating agent and oral solid preparation |
| 05/30/2001 | EP1103252A1 Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method |
| 05/30/2001 | EP1103192A1 Stable, spray-dried composition in a carbohydrate substrate and process for obtaining said composition |
| 05/30/2001 | EP1102862A1 Antisense oligonucleotides targeted to il-15 |
| 05/30/2001 | EP1102817A1 Cellulose fiber based compositions and film |
| 05/30/2001 | EP1102793A1 A process for the preparation of aqueous dispersions of latex particles having a heterogeneous morphology, the latex particles obtainable with the process, the dispersions and redispersible powders, as well as the use thereof |
| 05/30/2001 | EP1102792A1 Thermally-inhibited starch prepared with oligosaccharides |
| 05/30/2001 | EP1102784A1 A compound containing a labile disulfide bond |
| 05/30/2001 | EP1102779A2 Treatment of bacterial infections |
| 05/30/2001 | EP1102775A1 Novel phospholipids with unsaturated alkyl and acyl chains |
| 05/30/2001 | EP1102758A1 Particle-forming compositions containing fused pyrrolocarbazoles |
| 05/30/2001 | EP1102742A2 Compounds and compositions for delivering active agents |
| 05/30/2001 | EP1102601A1 Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells |
| 05/30/2001 | EP1102599A1 Protease inhibitors for use in the treatment of psoriasis |
| 05/30/2001 | EP1102598A1 Hair growth/maintenance compositions and methods involving the same |
| 05/30/2001 | EP1102597A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht 4 receptors |
| 05/30/2001 | EP1102594A1 Use of camptothecin derivatives, with reduced gastrointestinal toxicity |
| 05/30/2001 | EP1102592A1 Coumarin and related aromatic-based polymeric prodrugs |
| 05/30/2001 | EP1102581A1 A microemulsion forming composition for the sustained release of an active agent |
| 05/30/2001 | EP1102579A1 Medicinal aerosol formulations |
| 05/30/2001 | EP0886654B1 Thioureido-cyclodextrins particularly useful for solubilising antitumoral and antiparasitic agents, and methods for preparing same |
| 05/30/2001 | EP0840570A4 Apparatus and method for making gas-filled vesicles of optimal size |
| 05/30/2001 | EP0817610B1 Sterile ophthalmological gel preparation applicable in drops and process for producing it |
| 05/30/2001 | EP0689441B1 Pharmaceutical composition in form of a kit comprising prostaglandin e1 |
| 05/30/2001 | EP0662320B1 Dry gel composition |
| 05/30/2001 | CN1297480A Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies |
| 05/30/2001 | CN1297364A Preparation contg. calcium hydroxide, dehydric or polyvalent alcohol and fatty oil of vegetable or animal origin, and use thereof for regenerating collagen |
| 05/30/2001 | CN1297359A Ophthalmic composition comprising beta-blocker |
| 05/30/2001 | CN1297358A Glycolipid creams |
| 05/30/2001 | CN1297355A Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives |
| 05/30/2001 | CN1297344A Method and compositions for in situ formation of protective and/or medicated film on body tissue |
| 05/30/2001 | CN1296852A Chitosan/gelatin network modification on surface of aliphatic polyester |
| 05/29/2001 | US6239177 Dissolution medium of crotamiton and n-methyl-2-pyrrolidone |
| 05/29/2001 | US6239165 Liquid pharmaceutical formulation containing zotepine |
| 05/29/2001 | US6239141 Antibiotic |
| 05/29/2001 | US6239116 Immunostimulatory nucleic acid molecules |
| 05/29/2001 | US6239113 Topical treatment or prevention of ocular infections |
| 05/29/2001 | US6239107 Treatment of male impotence or treatment of neurodegenerative diseases |
| 05/29/2001 | US6239102 Concentrate comprising, as active agent, (3'-desoxy-3-oxo-mebmc)1-(val)2-cyclosporin, stabilizer selected from oleic acid or palmitoyl oleoyl phosphatidyl glycerol or salts thereof, ethanol |
| 05/29/2001 | US6238888 Keratinocyte growth factor-2 formulations |
| 05/29/2001 | US6238872 Inhibiting restenosis by inserting stent that has antigen attached, then administering antibody labeled with radioactive source; immunotherapy |
| 05/29/2001 | US6238698 Multilayer tablet |
| 05/29/2001 | US6238695 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
| 05/29/2001 | US6238692 Containing cyanoacrylate adhesive |
| 05/29/2001 | US6238689 Intestinal absorption of nicotine to treat nicotine responsive conditions |
| 05/29/2001 | US6238683 Drug delivery |
| 05/29/2001 | US6238670 Compositions and methods employing a ligand for CD21 or CD19 for modulating the immune response to an antigen |